Historic achievement: Abu Dhabi successfully tests UAE first gene therapy for genetic blood disorders

On January 5, 2026, Abu Dhabi marked a truly historic moment in medical care, the first administration of a gene-therapy injection for inherited blood disorders in the UAE. The treatment, called CASGEVY, uses a precise form of CRISPR-Cas9 gene editing to correct faulty DNA that causes serious conditions like sickle cell disease and beta thalassemia.

This step isn’t about managing symptoms anymore. It strikes at the root genetic cause, a shift from decades of supportive care (like regular transfusions and pain management) to actual correction of disease-causing errors inside the body’s own cells.

The therapy was given at Yas Clinic – Khalifa City, in partnership with the Abu Dhabi Stem Cells Center (ADSCC) and global biotech leader Vertex Pharmaceuticals, under the watchful supervision of the Department of Health, Abu Dhabi (DoH).

How gene therapy works?

Gene therapy is often painted as futuristic, but here’s the core idea in human terms:

• Extraction: Doctors collect the patient’s own stem cells, the basic building blocks for new blood.

• Editing: Scientists use the CRISPR-Cas9 “molecular scissors” to fix the broken gene that causes disease.

• Reinfusion: The corrected cells are returned to the body.

• Renewal: Over time, these cells help produce healthy, functioning blood cells, reducing or eliminating dependence on life-long treatments.

CRISPR technology pinpoints the faulty segment of DNA and snips it out, effectively re-writing a small part of the patient’s genetic code, a powerful leap forward in medicine.

Diseases this can cure

Gene therapy is not just a treatment; it is a specialized "biological repair kit." While this first milestone focused on blood disorders, the implications for the UAE’s healthcare landscape are massive. This technology is currently being harnessed to tackle some of the most challenging genetic conditions prevalent in the region:

• Beta Thalassemia: A condition where the body doesn't make enough hemoglobin, leading to severe anemia.
• Sickle Cell Disease: Where red blood cells become hard and "C-shaped," causing excruciating pain and organ damage.
• Spinal Muscular Atrophy (SMA): A genetic disease that affects muscle strength and movement, which gene therapy has already begun to transform for infants.
• Hemophilia: A rare disorder where the blood doesn't clot normally, which is now seeing "cures" through similar genetic interventions.

By targeting these "big four" diseases, Abu Dhabi is reducing the long-term burden on families and the healthcare system alike, moving from chronic care to permanent cures.

This achievement didn't happen by accident. It is the result of a massive, multi-year push by the Department of Health – Abu Dhabi (DoH) to turn the capital into a global destination for life sciences. Through initiatives like the Emirati Genome Program, the UAE has been building one of the world's most comprehensive genetic databases.

Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, stated: "This milestone is a testament to Abu Dhabi’s position as a global leader in healthcare innovation. By bringing the most advanced gene therapies to the UAE, we are not just treating patients; we are giving them back their lives and their futures."

Rollout strategy

While the first successful injection at Sheikh Shakhbout Medical City (SSMC) marks a historic win, the "common man" is likely wondering when they can book an appointment for this life-changing treatment. The Department of Health – Abu Dhabi (DoH) is currently following a rigorous, three-phase rollout plan to ensure safety and efficacy before making it a standard of care across all major hospitals.

Currently, we are in Phase 1: Specialized Centers. Because gene therapy requires highly specific lab conditions and expert hematologists, it is initially restricted to "Centers of Excellence" like SSMC. Over the next 6 to 12 months (through mid-2026), the program is expected to move into Phase 2, which involves expanding the number of certified hospitals and training more medical staff to administer the injections.

While access, cost, and long-term outcomes remain areas of focus, Abu Dhabi’s move shows what’s possible when innovation, collaboration, and patient needs intersect.

The era of gene therapy isn’t just on the horizon, it’s here.